Additional file 1 of The metabolic consequences of HIV/TB co-infection

Additional file 1: Table S1. Detailed clinical data for HIV-positive cohorts. Table S2. Fisher’s exact tests for categorical variables. Table S3. Stratification based on CD4 count. Table S4. Untreated co-infected group as used for analyses. Table S5. t-Test. Figure S1. Dendogram of the healthy controls versus untreated HIV/TB co-infected samples, after exclusion of the co-infected samples with high CD4 T-cell counts but before exclusion of any healthy controls. This figure shows that the 5 healthy controls indicated in red cluster with the diseased samples, and were subsequently excluded. Table S6. Fold Change. Table S7. t-Test. Table S8. Fold Change. Table S9. t-Test and FC. Table S10. PLS-DA. Figure S2. The validation results for the PLS-DA analysis of the healthy controls versus all the untreated patient samples. A: Leave-one-out cross-validation results, indicating that PLS-DA with one component is most applicable to these data, B: Permutation testing (frequency = 2000), indicating that the model is not random (significant p-value, 600 and selected healthy controls). Table S12. A count of the compounds significant in the ANOVA post-hoc analysis per compound class. Table S13. Results of the ANOVA including all groups (with exclusions of HIV+/TB+/Tn- samples with CD4 T cell count>600) and selected healthy controls, organized by compound class, and then by significance as per ANOVA post-hoc analysis. Table S14. The effect of untreated HIV/TB on the metabolome (untreated HIV/TB versus healthy controls). Table S15. The effect of HIV on TB (untreated TB vs untreated HIV/TB). Table S16. The effect of ART on HIV/TB (untreated HIV/TB versus treated HIV/TB). Table S17. Pearson's r correlation results for 3,4-DHBA and all other metabolites (from ANOVA). Figure S3. PLS-DA validation results for the comparison of all groups.